.jpeg)
2026-06-05 06:44:46
This article explains why mitotane, a drug for adrenocortical carcinoma, must not be stopped abruptly, and outlines a safe tapering protocol under medical supervision, including monitoring and management.
2026-06-05 06:17:52
Pemigatinib delivers breakthrough efficacy for patients with advanced cholangiocarcinoma harboring FGFR2 fusions/rearrangements, showing an objective response rate of 35.5% and a median overall survival of 21.1 months in a key study.
2026-06-05 06:10:25
Erlotinib is an oral EGFR tyrosine kinase inhibitor that works by precisely blocking the growth signaling pathways in non-small cell lung cancer cells harboring specific EGFR gene mutations, thereby inhibiting tumor progression.
2026-06-05 05:52:29
Tofacitinib is an oral JAK inhibitor that suppresses inflammation by blocking cytokine signaling pathways. It is approved for the treatment of various immune-mediated conditions including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
2026-06-05 05:46:25
Tucatinib, a highly selective HER2 tyrosine kinase inhibitor, is demonstrating key value in treating HER2-positive breast cancer with brain metastases and colorectal cancer. Its precise mechanism and favorable tolerability are advancing HER2-targeted therapy.
2026-06-04 03:40:01
This article systematically explains the acquired resistance phenomenon of Garsorasib, a KRAS G12C covalent inhibitor, and details common resistance mechanisms, standardized diagnostic procedures, individualized subsequent treatment strategies based on different resistance mechanisms, cutting-edge combination regimens and clinical trial opportunities, providing comprehensive reference for clinical management and patient treatment decisions.
2026-06-03 03:11:10
This article provides a detailed analysis of the oral BRAF inhibitor vemurafenib, explaining its mechanism of action against the BRAF V600E mutation, its central role in treating advanced melanoma, its potential in other rare conditions like Erdheim-Chester disease, and outlines its standard usage and key safety considerations.
2026-06-02 06:02:23
Vemurafenib is an oral targeted therapy that selectively inhibits the BRAF V600E mutant protein, offering a revolutionary treatment option for patients with specific types of melanoma and marking the era of "precision medicine" in oncology.
2026-05-29 07:46:00
A comprehensive analysis of the latest clinical data for the highly selective KRAS G12C inhibitor Garsorasib in NSCLC and solid tumors, covering first-line chemotherapy combinations, immunotherapy regimens, brain metastasis efficacy, and resistance management.
2026-05-27 02:05:59
Zongertinib (Hernexeos) gains FDA approval for HER2-mutated NSCLC, offering targeted therapy based on 76% response rate data, transforming treatment landscape.
2026-05-25 04:05:18
Explore the breakthrough of Sotorasib (AMG-510), the first approved KRAS G12C inhibitor. Detailed clinical trial data, dosage guidelines, and global pricing insights for patients in Hong Kong, Macau, and worldwide.
2026-05-22 04:06:55
LONSURF® (Trifluridine/Tipiracil) has become a cornerstone in the later-line treatment of metastatic colorectal cancer. This article explores its origins at Taiho Pharmaceutical, its unique mechanism of action, and the robust global manufacturing network ensuring its quality and availability.
